Oh-I, S
Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-week clinical study
Pero no entres en pnico, vamos a conocer las causas de su aparicin para que puedas prevenirlas y ver los diferentes tratamientos mas efectivos con los que podamos despedirnos de ellas
Observation periods included the in-trial period (that is, while in the trial, regardless of treatment discontinuation or rescue intervention) and the on-treatment period (with trial product)
Furthermore, SGLT2i reduce circulating catecholamine levels [60] and impact myocardial remodeling and fibrosis, through modulation of several chemokine pathways (IL-6, TNF-, monocyte chemoattractant protein-1), calcium homeostasis [61, 62], authophagy [60, 63,64,65,66,67,68] and RAAS inhibition [69] in pre-clinical models